Claims
- 1. A compound of the formula ##STR18## wherein R.sub.1 is C.sub.1-3 alkyl, and
- R.sub.7 is hydrogen, R.sub.8 or M,
- wherein
- R.sub.8 is a physiologically acceptable and hydrolyzable ester group, and
- M is a cation.
- 2. A compound according to claim 1 wherein M is a pharmaceutically acceptable cation.
- 3. A compound according to claim 2 wherein R.sub.7 is hydrogen, C.sub.1-3 alkyl or M, wherein M is a pharmaceutically acceptable cation.
- 4. A compound according to claim 3 wherein R.sub.7 is a pharmaceutically acceptable cation.
- 5. A compound according to claim 4 wherein R.sub.7 is sodium.
- 6. A compound according to claim 4 wherein R.sub.1 is methyl or isopropyl.
- 7. A compound according to claim 6 wherein R.sub.7 is sodium.
- 8. The compound according to claim 7 having the formula ##STR19##
- 9. The compound according to claim 3 having the formula ##STR20##
- 10. A pharmaceutical composition comprising an effective amount of a compound according to claim 2 and a harmaceutically acceptable carrier, said effective amount being an amount sufficient to inhibit cholesterol biosynthesis in a mammal.
- 11. A pharmaceutical composition according to claim 10 comprising an effective amount of the compound of the formula ##STR21## said effective amount being an amount sufficient to inhibit cholesterol biosynthesis in a mammal.
- 12. A method of inhibiting cholesterol biosynthesis comprising administering to a mammal in need of such treatment an effective amount of a compound according to claim 2, said effective amount being an amount effective for inhibiterol biosynthesis.
- 13. A method of treating atherosclerosis comprising administering to a mammal in need of such treatment an effective amount of a compound according to claim 2, said effective amount being an amount effective for the treatment of atherosclerosis.
- 14. A method of treating atherosclerosis according to claim 13 comprising administering to a mammal in need of such treatment an effective amount of a compound of the formula ##STR22##
- 15. A method of treating atherosclerosis according to claim 14 comprising administering to a mammal in need of such treatment an effective amount of the compound of the formula ##STR23## said effective amount being an amount effective for the treatment of atherosclerosis.
Parent Case Info
This application is a continuation of application Ser. No. 633,809, filed July 24, 1984 and now abandoned.
US Referenced Citations (12)
Foreign Referenced Citations (2)
Number |
Date |
Country |
0895445 |
Apr 1983 |
BEX |
0038061 |
Oct 1981 |
EPX |
Non-Patent Literature Citations (4)
Entry |
Derwent Abstracts 20213 D/12, JP 56-7775 (1/27/81) Sankyo KK. |
Hulcher, Arch. Biochem. Biophys. 146, 422-427 (1971). |
Sato et al., Chem. Pharm. Bull. 28, 1509-1525 (1980). |
Singer et al., Proc. Soc. Exp. Biol. Med. 102, 370-373 (1959). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
633809 |
Jul 1984 |
|